EyePoint (EYPT) Liabilities and Shareholders Equity (2011 - 2026)

EyePoint (EYPT) posted Liabilities and Shareholders Equity of $288.2 million for Q1 2026, down 20.82% sequentially from $364.0 million in Q4 2025, and down 20.51% YoY from $362.6 million in Q1 2025.

EyePoint (EYPT) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends

EyePoint has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $288.2 million in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity fell 20.51% year-over-year to $288.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 billion (down 14.3% YoY) and the FY2025 annual result came in at $364.0 million, down 13.02% from the prior year.
  • Liabilities and Shareholders Equity fell to $288.2 million in Q1 2026 per EYPT's latest filing, from $364.0 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $418.5 million in Q4 2024 and troughed at $154.6 million in Q1 2023.
  • A 5-year average of $274.4 million and a median of $288.2 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
  • The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity tumbled 36.79% in 2023, then soared 112.98% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $180.4 million in 2022, then jumped by 96.93% to $355.2 million in 2023, then climbed by 17.82% to $418.5 million in 2024, then retreated by 13.02% to $364.0 million in 2025, then declined by 20.82% to $288.2 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $288.2 million, $364.0 million, and $251.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 10.03 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 4.32 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 9.18 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 15.59 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 19.82 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 5.56 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 2.10 Bn
10 EyePoint 1.25 Bn 1.07 Bn 507,000.00 228.19 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 228.19 Mn
Mar 31, 2026 288.22 Mn
Dec 31, 2025 364.00 Mn
Sep 30, 2025 251.70 Mn
Jun 30, 2025 301.15 Mn
Mar 31, 2025 362.56 Mn
Dec 31, 2024 418.47 Mn
Sep 30, 2024 300.92 Mn
Jun 30, 2024 324.25 Mn
Mar 31, 2024 329.25 Mn
Dec 31, 2023 355.18 Mn
Sep 30, 2023 160.04 Mn
Jun 30, 2023 175.66 Mn
Mar 31, 2023 154.59 Mn
Dec 31, 2022 180.36 Mn
Sep 30, 2022 220.49 Mn
Jun 30, 2022 233.43 Mn
Mar 31, 2022 244.56 Mn
Dec 31, 2021 263.37 Mn
Sep 30, 2021 168.25 Mn